Mumbai, India – Blue Jet Healthcare Limited, a prominent player in the Indian pharmaceutical and healthcare ingredient sector, has achieved a significant milestone with the successful conclusion of its Initial Public Offering (IPO). This pivotal event garnered substantial interest from investors and was oversubscribed nearly eight times, emphasizing the robust demand for the company’s distinctive product portfolio. The total issue size of the IPO amounted to ₹840.27 crores (INR100 crore ≈ USD12 million).
Blue Jet Healthcare specializes in a niche market characterized by formidable entry barriers, where it manufactures unique products including contrast media intermediates and high-intensity sweeteners. The company’s production operations are spread across three state-of-the-art manufacturing facilities situated in Maharashtra.
The IPO’s closing date was this past Friday, October 27, with the basis of allotment set to be finalized today. Investors can anticipate having their allotted shares credited to their demat accounts by Friday, November 3. Furthermore, the company’s shares are slated for listing on both the Bombay Stock Exchange (BSE) and the National Stock Exchange (NSE) on Monday, November 6.
The offer for sale incorporated a total of 24,285,160 shares, each carrying a face value of ₹2 per share, within a price band of ₹329 to ₹346 per share.
